logo
Share SHARE
FONT-SIZE Plus   Neg

Capita To Buy Northgate Managed Services For £65 Mln

UK-based professional support solutions provider Capita Group Plc (CPI.L) said Thursday it is buying Northgate Managed Services Limited, or NMS, from Northgate Information Solutions for an enterprise value of 65 million pounds.

The purchase price comprises 22 million pounds payable in cash and, in addition, the assumption by Capita of a pension deficit of 17 million pounds, net of tax relief, and finance leases for equipment used in the business of 26 million pounds.

Northgate Managed Services, which had a turnover of 141.6 million pounds in 2012, provides cloud-based, infrastructure solutions and specialist managed services to public, private and third sector businesses.

Commenting on the acquisition, Paul Pindar, Chief Executive of Capita plc, said, "...By combining NMS's managed IT services with Capita's complementary business process and IT outsourcing capabilities, Capita will enhance its offering to clients and enable them to transform the way they do business."

The completion of the acquisition is subject to approvals from the necessary parties, added Capita.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Coca-Cola Company (KO) reported a profit for the first-quarter of 2017 that declined 20 percent from the prior year. Net revenues declined 11%, reflecting unfavorable impacts from structural changes of 10% and foreign currency of 1%. The company remains on track to deliver its underlying revenue and profit targets for the full year. Eli Lilly and Co. (LLY) reported a loss for the first quarter of 2017 compared to profit in the prior year, primarily hurt by lower operating income, partially offset by higher other income. But, quarterly revenue increased 7 percent, driven by 9 percent pharmaceutical volume growth from Trulicity, Taltz and other new products. Capricor Therapeutics, Inc., a clinical-stage biotechnology company for cardiac and other medical conditions, announced Tuesday positive six-month results from the randomized phase I/II HOPE clinical trial in Duchenne muscular dystrophy or DMD. The HOPE clinical trial was designed to evaluate the safety and exploratory efficacy of CAP-1002.
comments powered by Disqus
Follow RTT